List of Excipients in Branded Drug CYSTARAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Leadiant Biosciences Inc	CYSTARAN	cysteamine hydrochloride	54482-020	BENZALKONIUM CHLORIDE
Leadiant Biosciences Inc	CYSTARAN	cysteamine hydrochloride	54482-020	HYDROCHLORIC ACID
Leadiant Biosciences Inc	CYSTARAN	cysteamine hydrochloride	54482-020	SODIUM CHLORIDE
Leadiant Biosciences Inc	CYSTARAN	cysteamine hydrochloride	54482-020	SODIUM HYDROXIDE

Cystaran Excipient Strategy, Formulation Patents, Generic Risk, and Commercial Opportunities

Last updated: September 16, 2026

Cystaran is a preservative-free cysteamine ophthalmic solution for corneal cystinosis. Its main commercial weakness is the intensive dosing burden: patients typically instill one drop in each eye every waking hour. The strongest excipient opportunities therefore involve ocular residence time, oxidation control, multidose packaging, cold-chain reduction, and manufacturing consistency. Cystaran’s original orphan-drug exclusivity has expired, while formulation, container-closure, manufacturing, and method-of-use rights remain the principal potential barriers to competition.

What is Cystaran and how does its formulation work?

Cystaran contains cysteamine hydrochloride ophthalmic solution at 0.44%, equivalent to approximately 0.37% cysteamine. It is indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. The product is administered frequently during waking hours because cysteamine has limited ocular residence time and the target corneal crystals require sustained repeated exposure (FDA, 2012).

Attribute	Cystaran
Active ingredient	Cysteamine hydrochloride
Strength	0.44% solution
Equivalent cysteamine concentration	Approximately 0.37%
Dosage form	Sterile ophthalmic solution
Primary indication	Corneal cystinosis
Dosing burden	One drop in each eye every waking hour
Preservative status	Preservative-free
Regulatory route	FDA NDA
FDA approval	2012
Exclusivity category	Orphan-drug exclusivity at approval
Primary formulation challenge	Cysteamine oxidation and short ocular residence time

Cysteamine is chemically vulnerable to oxidation, including conversion to cystamine. The product therefore requires controlled storage and handling. The formulation must maintain cysteamine potency without introducing excipients that promote oxidation, alter pH materially, or compromise ocular tolerability.

What excipients are used in Cystaran?

The Cystaran label identifies hydrochloric acid and sodium hydroxide as inactive ingredients used for pH adjustment. The formulation is preservative-free, which reduces chronic exposure to benzalkonium chloride and similar preservatives in a population requiring frequent lifelong administration (FDA, 2012).

The limited excipient profile creates both advantages and constraints.

Formulation element	Strategic function	Commercial implication
Hydrochloric acid	pH adjustment	Low differentiation; routine supply
Sodium hydroxide	pH adjustment	Low differentiation; routine supply
No conventional preservative	Chronic ocular tolerability	Raises multidose-container and sterility-control requirements
Aqueous vehicle	Delivers cysteamine to cornea	Limits residence time and may increase oxidation risk
Refrigerated storage	Supports stability	Creates logistics and adherence friction

The absence of a viscosity-enhancing polymer in the original solution leaves room for reformulation. A polymer can improve retention, but it can also create new risks involving clarity, drop size, drug release, ocular comfort, sterilization, and equivalence testing.

What excipient strategies could improve Cystaran?

How can viscosity enhancers create a commercial opportunity?

The most direct lifecycle strategy is a low-viscosity or gel-forming vehicle that extends precorneal residence time. Candidate excipient classes include:

• Carmellose sodium
• Hydroxypropyl methylcellulose
• Hydroxypropyl cellulose
• Polyvinyl alcohol
• Povidone
• Sodium hyaluronate
• Poloxamers
• In situ gelling polymers

The objective is not maximum viscosity. Excessive viscosity can cause blurred vision, sticky ocular sensation, variable dosing, and poor patient acceptance. A commercially viable formulation would need to show a meaningful reduction in daily instillation frequency while preserving cysteamine availability at the corneal surface.

Carmellose sodium is particularly relevant because cysteamine ophthalmic products using a more viscous vehicle have established commercial precedent. Cystadrops, another cysteamine ophthalmic product, uses a viscous formulation and is dosed less frequently than Cystaran. Its formulation includes carmellose sodium and other buffering and chelating components (FDA, 2020).

Which excipients can address cysteamine oxidation?

Oxidation control is a central formulation issue. Potential approaches include:

1. Chelation of trace metal ions through an agent such as disodium EDTA.
2. Reduced dissolved oxygen through nitrogen purging or controlled filling.
3. Low-oxygen container-closure systems.
4. Antioxidant systems compatible with ophthalmic administration.
5. Optimized pH and buffer capacity.
6. Use of high-purity water and low-peroxide excipient grades.

EDTA is attractive because it can bind catalytic metal impurities and has precedent in ophthalmic formulations. Its inclusion must be evaluated against ocular tolerability, compatibility with the container, and any effect on cysteamine stability.

Conventional antioxidants require greater caution. Sulfites, metabisulfites, ascorbate systems, and other reducing agents may create tolerability, color, pH, or regulatory issues. A formulation that relies on packaging and oxygen control rather than a reactive antioxidant may present a cleaner regulatory and commercial profile.

Can preservatives improve Cystaran economics?

A conventional preservative could simplify multidose packaging, but it would conflict with the product’s chronic, frequent-use profile. Benzalkonium chloride is associated with ocular-surface toxicity, particularly with repeated administration. A preserved Cystaran substitute would face a significant clinical and commercial disadvantage unless it reduced dosing frequency substantially.

More commercially relevant approaches include:

• Preservative-free multidose valves
• Sterile unit-dose ampoules
• Blow-fill-seal packaging
• Refillable sterile cartridges
• One-way dispensing systems
• Low-dead-volume droppers

The best opportunity may be a preservative-free container that supports longer in-use dating without adding antimicrobial preservatives.

What formulations are protected by Cystaran and competing products?

Cystaran and Cystadrops illustrate two distinct formulation strategies.

Product	Formulation profile	Dosing profile	Strategic position
Cystaran	Preservative-free aqueous cysteamine solution	Every waking hour	Established product with high administration burden
Cystadrops	More viscous cysteamine formulation	Four times daily	Differentiated residence-time strategy

Cystadrops was approved by FDA in 2020 for corneal cystinosis. The product contains carmellose sodium, disodium EDTA, citric acid, sodium citrate, sodium hydroxide, and water for injection, according to its prescribing information (FDA, 2020).

This comparison identifies the principal formulation white space: a stable, preservative-free cysteamine product with the dosing convenience of a viscous formulation but lower blur, lower drop variability, and easier manufacturing.

Potential claim categories for a new product include:

• Cysteamine concentration and pH ranges
• Specific polymer combinations
• Polymer-to-cysteamine ratios
• EDTA or chelator concentration
• Dissolved oxygen limits
• Container headspace composition
• Multidose preservative-free dispensing
• In-use stability after opening
• Reduced dosing frequency
• Manufacturing controls that limit cystamine formation
• Packaging configurations that preserve potency

Patentability would depend on unexpected technical results, such as a statistically significant stability improvement, longer in-use period, lower cystamine formation, or improved corneal retention.

When does Cystaran lose exclusivity?

Cystaran’s seven-year orphan-drug exclusivity followed its FDA approval in 2012 and therefore expired in 2019, assuming no separate extension controlled the relevant indication. Orphan exclusivity prevents FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions. It does not block all competing formulations or products.

Regulatory right	Cystaran status
Orphan-drug exclusivity	Expired after the seven-year period beginning in 2012
New chemical entity exclusivity	Not the principal commercial barrier
Pediatric exclusivity	No controlling pediatric extension is identified in the cited public labeling
Patent protection	Must be assessed through current FDA Orange Book and USPTO records
Generic pathway	Potentially available, subject to product-specific equivalence and regulatory requirements

The expiration of orphan exclusivity does not automatically establish that an ANDA can be approved. A generic sponsor must still address formulation sameness, sterility, stability, container closure, specifications, and labeling.

What is the Orange Book status of Cystaran?

The Orange Book is the controlling FDA source for approved drug products, listed patents, and exclusivity information. Cystaran should be evaluated under its NDA number and current product listing rather than by relying only on commercial patent databases (FDA, 2024).

For a competitive diligence review, the relevant questions are:

• Whether Cystaran has active patent listings in the Orange Book.
• Whether listed patents cover the solution, dosage regimen, container, or manufacturing process.
• Whether any patent certifications have been filed.
• Whether the reference product has an active exclusivity block.
• Whether an ANDA sponsor can use a Paragraph III or Paragraph IV certification.

A patent not listed in the Orange Book can still create litigation exposure, particularly if it covers manufacturing, packaging, or a method of treating cystinosis. Conversely, an Orange Book-listed patent does not guarantee commercial enforceability.

Which companies are challenging Cystaran?

The competitive field includes generic ophthalmic manufacturers, specialty pharmaceutical companies, and developers of differentiated cysteamine products. Publicly documented market competition is more visible through Cystadrops than through a clearly established wave of approved Cystaran generics.

A Paragraph IV challenger would likely target one or more of the following:

• Active-ingredient equivalence
• Inactive-ingredient differences
• Container-closure performance
• In-use stability
• Sterility assurance
• Labeling differences
• Absence of active patents
• Noninfringement of formulation or method-of-use claims

A generic applicant may face a difficult development program even where patent barriers are limited. Preservative-free ophthalmic products require robust microbiological controls, drop-size consistency, extractables and leachables testing, and stability data after repeated opening.

What generic entry risks exist for Cystaran?

Generic entry risk is moderate from a regulatory perspective but technically meaningful. The product contains a simple active ingredient and a relatively limited excipient system, which supports generic development. The main obstacles are product stability and sterile multidose delivery.

Regulatory risks

FDA may scrutinize:

• Cysteamine assay and impurity profile
• Cystamine formation during shelf life
• pH and osmolality
• Sterility and particulate matter
• Drop volume and delivered dose
• Container-closure integrity
• In-use microbiological stability
• Storage and shipping excursions

A formulation with different excipients could require a more complex regulatory justification. A visibly different or more viscous product may be better positioned as a 505(b)(2) product rather than a conventional ANDA, depending on the proposed changes and FDA determinations.

Commercial risks

Cystaran’s high dosing frequency creates an opening for a lower-frequency competitor. A generic that matches the original solution but does not improve convenience could compete primarily on price and supply reliability. A differentiated formulation could compete on adherence, but it would likely require clinical or human-factor evidence and may encounter separate intellectual-property claims.

How strong is the Cystaran patent estate?

The commercial strength of the estate depends less on the original aqueous solution than on any active claims covering formulation improvements, packaging, manufacturing controls, and dosing regimens.

Patent category	Expected strategic value
Basic cysteamine composition	Low if expired or broadly known
Simple aqueous solution	Moderate only if narrow technical limitations apply
Viscosity-enhanced formulation	High if supported by unexpected stability or efficacy data
Preservative-free multidose package	Moderate to high
Oxygen-control manufacturing	Moderate
Reduced-frequency dosing	High if clinically supported and claim scope is durable
Method of treating corneal cystinosis	Variable; depends on claim construction and prior art
Manufacturing process	Important for supply control but often harder to enforce against distant competitors

Cystadrops demonstrates that formulation differentiation can support a separate commercial position even when the active ingredient is old. Its excipient system and dosing regimen provide a useful benchmark for designing around existing claims rather than copying the product directly.

What licensing and commercial opportunities exist?

The most practical licensing opportunities are outside the active pharmaceutical ingredient.

Excipient and formulation licensing

Potential partners include suppliers with proprietary:

• Ocular mucoadhesive polymers
• In situ gelling systems
• Low-peroxide excipients
• Chelation platforms
• Ophthalmic-grade antioxidant systems
• Preservative-free multidose technology

A licensor should seek claims covering composition, manufacturing, and container integration. A polymer-only patent may be easy to design around unless the combination with cysteamine produces a measurable stability or dosing benefit.

Device and packaging licensing

Packaging technology can create a defensible commercial package when the formulation itself is difficult to patent. Relevant systems include:

• Preservative-free multidose bottles
• One-way valve droppers
• Unit-dose systems
• Sterile cartridge devices
• Oxygen-barrier bottles
• Nitrogen-filled containers

A device partnership could reduce cold-chain dependence or extend in-use dating. Those outcomes may improve pharmacy handling, international distribution, and patient adherence.

Generic and specialty-product opportunities

A generic manufacturer could pursue a low-cost Cystaran equivalent. A specialty company could develop a lower-frequency product using a viscous or gel-forming vehicle. A third strategy would combine a stable formulation with a dispensing device that reduces waste and improves dose reproducibility.

The strongest value proposition is likely a product that reduces administration from hourly use to several times daily without causing substantial visual blur or ocular discomfort.

How does Cystaran compare with Cystadrops?

Cystaran competes through established availability and a simple preservative-free solution. Cystadrops competes through formulation differentiation and lower dosing frequency.

Factor	Cystaran	Cystadrops
Active ingredient	Cysteamine hydrochloride	Cysteamine hydrochloride
Vehicle	Aqueous solution	Viscous formulation
Dosing	Every waking hour	Four times daily
Excipient differentiation	Limited	Polymer, chelator, buffer system
Main weakness	Administration burden	Potential viscosity-related tolerability and manufacturing complexity
Lifecycle lesson	Basic solution has limited differentiation	Excipients can support convenience claims

What manufacturing and IP barriers matter most?

The highest-value technical barrier is consistent cysteamine stability from batch release through patient use. Key manufacturing controls include:

• Low-oxygen processing
• Tight control of metal contamination
• Excipient peroxide limits
• Controlled pH adjustment
• Sterile filtration or validated aseptic processing
• Container-closure integrity
• Light and temperature protection
• Monitoring of cystamine and related impurities

These controls can support trade secrets even where patent protection is weak. A manufacturer with validated low-oxidation processes, reliable sterile filling, and global supply capacity may gain a practical advantage over a nominally equivalent competitor.

Key Takeaways

• Cystaran is a preservative-free cysteamine ophthalmic solution for corneal cystinosis.
• Its principal commercial weakness is hourly dosing during waking hours.
• The highest-value excipient opportunity is a viscosity-enhanced formulation that extends ocular residence time without causing blur or discomfort.
• EDTA, oxygen control, low-peroxide excipients, and improved container systems are relevant to cysteamine stability.
• Conventional preservatives are commercially unattractive because patients require chronic, frequent administration.
• Cystaran’s orphan-drug exclusivity expired after the seven-year period following its 2012 approval.
• Generic entry is technically feasible but requires strong sterility, in-use stability, container, and impurity-control data.
• Cystadrops is the primary formulation benchmark because it uses a more viscous vehicle and lower dosing frequency.
• The strongest new IP positions are likely to cover formulation combinations, oxygen-control methods, preservative-free multidose delivery, and reduced-frequency dosing.
• Packaging, CDMO manufacturing, excipient supply, and specialty-product licensing offer commercial opportunities beyond a direct generic.

FAQs

Can a new excipient formulation of Cystaran qualify for 505(b)(2) approval?

Yes. A formulation with a materially different vehicle, dosing frequency, or delivery system may be positioned through the 505(b)(2) pathway, subject to FDA assessment of the proposed changes and supporting data.

Is carmellose sodium suitable for cysteamine ophthalmic products?

Carmellose sodium is a commercially relevant candidate because it can increase viscosity and ocular residence time. The formulation must control blur, drop size, cysteamine stability, sterility, and patient comfort.

Does a preservative-free bottle require special patent protection?

No. A company can commercialize a preservative-free container without a patent, but patent claims covering the valve, oxygen barrier, dispensing mechanism, or in-use stability can improve market protection.

What is the most important impurity in cysteamine ophthalmic development?

Cystamine is a central stability-related impurity because cysteamine can oxidize to cystamine. Control of oxygen, trace metals, pH, excipient quality, and storage conditions is therefore critical.

Can a generic manufacturer copy Cystaran’s dosing schedule?

A generic product normally must use labeling consistent with the reference product unless FDA approves a different dosing regimen. A lower-frequency regimen generally requires separate evidence and may implicate method-of-use or formulation rights.

References

1. U.S. Food and Drug Administration. (2012). Cystaran (cysteamine hydrochloride ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2020). Cystadrops (cysteamine hydrochloride ophthalmic solution) prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.